Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00242424
Recruitment Status : Completed
First Posted : October 20, 2005
Last Update Posted : January 28, 2009
Sanofi Pasteur, a Sanofi Company
Information provided by:
Seattle Children's Hospital

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2006
  Actual Study Completion Date : September 2007
Publications of Results:
Englund JA, Walter EB, Black S, et al. Safety and Immunogenicity of Fluzone Trivalent Inactivated Influenza Vaccine (TIV) in Infants 6-12 Weeks of Age. Presented at Infectious Disease Society of America (IDSA), Toronto, Oct. 14, 2006